ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) Share Price

Company Profile

Business description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
Contact
1000 Zhangheng Road
Unit 15, China (Shanghai) Pilot Free Trade Zone
Pudong New Area
Shanghai
CHN
T: +86 2138016387
https://cn.immuneonco.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
195

Recommended

Cost-cutting the priority as underlying asset values falling on deaf ears.

Brian Han | 19 January 2026

We raise our fair value estimate for Goldman Sachs stock.

Sean Dunlop, CFA | 18 January 2026

We’ve adjusted our fair values after updating our commodity price assumptions.

Jon Mills, CFA | 18 January 2026

Index	Last price	Change	% Change
All Ordinaries	9,143.30	15.00	-0.16%
CAC 40	8,112.02	146.92	-1.78%
DAX 40	24,959.06	338.07	-1.34%
Dow JONES (US)	49,359.33	83.11	-0.17%
FTSE 100	10,195.35	39.94	-0.39%
HKSE	26,552.57	11.33	-0.04%
NASDAQ	23,515.39	14.63	-0.06%
Nikkei 225	52,984.25	599.32	-1.12%
NZX 50 Index	13,545.09	35.20	-0.26%
S&P 500	6,940.01	4.46	-0.06%
S&P/ASX 200	8,822.10	14.50	-0.16%
SSE Composite Index	4,101.62	12.38	-0.30%